

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS :	Calabresi, et al.	EXAMINER :	To be assigned
SERIAL NUMBER :	To be assigned	ART UNIT :	1616
FILING DATE :	March 8, 2004		
FOR :	USE OF TAUROLIDINE TO TREAT TUMORS		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being filed concurrently with the filing of the application. Accordingly, no fee or certification is believed required.

The references indicated on the attached modified Form PTO-1449 are enclosed herewith. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.


Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Applicants: Calabresi et al.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit
Account No. 50-0311, Reference No. 21486-031CON2.

Respectfully submitted,

Date: March 8, 2004

 Reg. No. 45,899
Ingrid A. Beattie, Reg. No. 42,306
for Attorney for the Applicant
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

TRA 1894017v1

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	To be assigned
	Filing Date	March 8, 2004
	First Named Inventor	Calabresi
	Group Art Unit	1616
	Examiner Name	To be assigned
	Attorney Docket Number	21486-031CON2

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	3,423,408	01/21/69	Pfirmann	260	243	
	A2	3,963,706	06/15/76	Pfirmann	260	239.9	
	A3	4,096,241	06/20/78	Geistlich et al.	424	54	
	A4	4,107,305	08/15/78	Pfirmann	424	246	
	A5	4,226,858	10/07/80	Pfirmann	424	125	
	A6	4,337,251	06/29/82	Pfirmann	424	246	
	A7	4,587,268	05/06/86	Pfirmann	514	774	
	A8	4,604,391	08/05/86	Pfirmann	514	222	
	A9	4,626,536	12/02/86	Pfirmann	514	222	
	A10	4,772,468	09/20/88	Pfirmann	424	128	
	A11	5,210,083	05/11/93	Pfirmann	514	222.5	
	A12	5,573,771	11/12/96	Geistlich et al.	424	422	
	A13	5,593,665	01/14/97	Pfirmann et al.	424	85.1	
	A14	5,819,748	10/13/98	Pfirmann	128	898	
	A15	5,972,933	10/26/99	Pfirmann	514	222.5	
	A16	5,954,687	09/21/99	Baudino	604	48	
	A17	5,976,822	11/2/99	Landrum et al.	435	23	
	A18	6,011,030	01/04/00	Pfirmann	514	222.2	
	A19	6,080,397	06/27/00	Pfirmann et al.	424	78.08	
	A20	6,117,868	09/12/00	Pfirmann	514	222.5	
	A21	6,303,596	10/16/01	Morrissey et al.	514	222.5	

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1	WO	91/13628	Pfirmann et al.	09/19/91		
	B2	WO	92/00743	ED Geistlich Sohne AG fur Chemische Industrie	01/23/92		
	B3	WO	98/52572	Oklahoma Medical Research Foundation	11/26/98		
	B4	WO	99/06114	ED Geistlich Sohne AG fur Chemische Industrie	02/11/99		
	B5	WO	99/34805	ED Geistlich Sohne AG fur Chemische Industrie	07/15/99		
	B6	EPO	0253662	ED Geistlich Sohne AG fur Chemische Industrie	01/20/88		
	B7	EPO	1066830	ED Geistlich Sohne AG fur Chemische Industrie	01/10/01		

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B8	WO	90/06138	Holmes et al	05/14/90	
	B9	WO	94/03174	Holmes et al	02/17/94	
OTHER NON PATENT LITERATURE DOCUMENTS						
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
	C1	Blenkhar et al. (1987) "The Antibacterial and Anti-Endotoxin Activity of Taurolidine in Combination with Antibiotics," Surg. Res. Commun., 2:149-155				
	C2	Browne M.K. et al. (1985) "Studies on the Antiendotoxin Properties of Taurolin in Animals and Man," <i>Recent Advances in Chemotherapy</i> , Proceedings of the 14 th International Congress of Chemotherapy, Kyoto, pp. 2075-2076.				
	C3	Browne M.K. et al. (1976) "Taurolin, a New Chemotherapeutic Agent," <i>The Journal of Applied Bacteriology</i> , Vol. 41, pp. 363-368.				
	C4	Geistlich Catalog, "Taurolin, Triad antimicrobial chemotherapy" pp. 1-95.				
	C5	Gorman et al. (1987) "Reduced Adherence of Micro -Organisms to Human Mucosal Epithelial Cells Following Treatment with Taurolin, a Novel Antimicrobial Agent," J. App. Bacteriol., 62:315-320				
	C6	Hamik, A. et al. (1997) "Taurolidine Inhibits Tissue Factor Expression in Monocytes," <i>Abstract from the XVth Congress of the International Society on Thrombosis and Haemostasis</i> , Florence, June 6-12.				
	C7	Jacobi, C. et al. (1999) "New Therapeutic Strategies to Avoid Intra- and Extraperitoneal Metastases during Laparoscopy: Results of a Tumor Model in the Rat," <i>Digestive Surgery</i> , Vol. 16 (5), pp. 393-399.				
	C8	Jacobi, C. et al. (1997) "Inhibition of Peritoneal Tumor Cell Growth and Implantation in Laparoscopic Surgery in a Rat Model," <i>The American Journal of Surgery</i> , Vol. 174 (3), pp. 359-363.				
	C9	Jacobi, C. et al. (1999) "Influence of Different Gases and Intraperitoneal Instillation of Antiadherent of Cytotoxic Agents on Peritoneal Tumor Cell Growth and Implantation with Laproscopic Surgery in a Rat Model," <i>Surg. Endos.</i> 13:1021-25.				
	C10	Knight et al., (1983) "NMR Studies and GC Analysis of the Antibacterial Agent Taurolidine," J. Pharm. Sci. 72:705-707				
	C11	Leaper et al. (1985) "Prevention of peritoneal adhesions after thermal injury using the formaldehyde carriers noxythidin and Taurolin," <i>Br. Soc. Gastroenterology</i> , page A901.				
	C12	McCourt, M. et al. (2000) "Taurolidine Inhibits Tumor Cell Growth In Vitro and In Vivo," <i>Annals of Surgical Oncology</i> , Vol.. 7(9), pp. :685-691.				
	C13	Monson, J.R.T. et al. (1990) "Preliminary evidence that taurolidine is anti-neoplastic as well as anti-endotoxin and anti-microbial," <i>The British Journal of Surgery</i> , Vol. 77(6), pp. 711.				
	C14	Monson, J.R.T. et al. (1990) "Taurolidine as an anti-neoplastic agent: a previously undiscovered role?" <i>The British Journal of Surgery</i> , Vol. 77(12).				
	C15	Monson, J.R.T. et al., (1993) "Taurolidine inhibits tumor necrosis factor (TNF) toxicity new evidence of TNF and endotoxin synergy," <i>European Journal of Surgical Oncology</i> , 19:226-231.				
	C16	Reymond, M.A. et al. (2000) "Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator," <i>Surgical Endoscopy</i> , Vol. 14(1), pp. 51-55.				
	C17	Umpleby, H. et al. (1984) "The efficacy of agents employed to prevent anastomotic recurrence in colorectal carcinoma," <i>Annals of the Royal College of Surgeons of England</i> , 66:192-194.				
	C18	Volz J. et al. (2000) "Modulation of Tumor-Induced Lethality after Pneumoperitoneum in a Mouse Model," <i>Cancer</i> , Vol. 89(2), pp. 262-266.				
	C19	Wicki, O. et al. (1983) "Solution for Surgical Lavage," <i>Langenbecks Archiv für Chirurgie</i> , p. 778, Abstract 276.				
	C20	International Search Report for PCT/US00/33103, mailed December 3, 2001.				

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail Label No.: EV138522256US

Date of Deposit: March 5, 2004

Attorney Docket No. 21486-031CON2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS Calabresi *et al.*

FOR: USE OF TAUROLIDINE TO TREAT TUMORS

Mail Stop Patent Application

Commissioner for Patents

P. O. Box 1450


Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT AND ACCOMPANYING
FORM PTO-1449**

Applicants submit herewith copies of modified PTO-1449 forms submitted in parent application USSN 09/730,923 from which the presently filed application claims priority. Copies of the references listed therein are not enclosed but will be provided upon request. Applicants request that each of the listed documents be made of record in the presently filed application.

This information disclosure statement is being submitted concurrently with the filing of the application. Accordingly, no fee is believed due. However, the Commissioner is authorized to charge any fees due, or credit overpayments of same, to Deposit Account No. 50-0311, Ref. No. 21486-031CON2.

Respectfully submitted,

 Christina K. Stock, Reg. No. 45,899
Ingrid A. Beattie, Reg. No. 42,306
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: March 8, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Calabresi *et al.*
ASSIGNEE: Rhode Island Hospital, A LifeSpan Partner
SERIAL NUMBER: 09/730,923 EXAMINER: Not Yet Assigned
FILING DATE: December 6, 2000 ART UNIT: 1619
FOR: USE OF TAUROLIDINE TO TREAT TUMORS

August 22, 2001
Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being filed more than three months after the filing date of this application and after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311.

- ☐ The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.
- ☒ The Applicant hereby certifies, as specified in 37 C.F.R. §1.97(e), that:
(Check a or b below)
- ☐ a. Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart for this application not more than three months prior to the filing of this Statement.
- ☒ b. No item of Information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart for this application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Statement.

APPLICANTS: Calabresi *et al.*
U.S.S.N.: 09/730,923


Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21486-031.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Ingrid A. Beattie, Reg. No. 42,306
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: August 22, 2001

TRA 1529065v1

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/730,923
	Filing Date	December 6, 2000
	First Named Inventor	Paul Calabresi
	Group Art Unit	1619
	Examiner Name	Unknown
	Attorney Docket Number	21486-031

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	AA	3,423,408	01/21/69	Pfirrmann	260	243	
	AB	3,963,706	06/15/76	Pfirrmann	260	239.9	
	AC	4,096,241	06/20/78	Geistlich et al.	424	54	
	AD	4,107,305	08/15/78	Pfirrmann	424	246	

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	BA	WO	91/13628	Pfirrmann et al.	09/19/91	X	
	BB	WO	92/00743	Monson	01/23/92	X	
	BC	WO	98/52572	Morrissey	11/26/98	X	
	BD	WO	99/06114	Pfirrmann	02/11/99	X	
	BE	WO	99/34805	Geistlich	07/15/99	X	
	BF	EPO	0253662	Geistlich	01/20/88	X	
	BG	EPO	1066830	Geistlich	01/10/01	X	

OTHER NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	CA	Blenkham et al. (1987) "The Antibacterial and Anti-Endotoxin Activity of Taurolidine in Combination with Antibiotics," Surg. Res. Commun., 2:149-155
	CB	Browne M.K. et al. (1985) "Studies on the Antiendotoxin Properties of Taurolin in Animals and Man," <i>Recent Advances in Chemotherapy</i> , Proceedings of the 14 th International Congress of Chemotherapy, Kyoto, pp. 2075-2076.
	CC	Browne M.K. et al. (1976) "Taurolin, a New Chemotherapeutic Agent," <i>The Journal of Applied Bacteriology</i> , Vol. 41, pp. 363-368.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/730,923
	Filing Date	December 6, 2000
	First Named Inventor	Paul Calabresi
	Group Art Unit	1619
	Examiner Name	Unknown
	Attorney Docket Number	21486-031

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	AE	4,226,858	10/07/80	Pfirmann	424	195	
	AF	4,337,251	06/29/82	Pfirmann	424	246	
	AG	4,587,268	05/06/86	Geistlich et al.	514	774	
	AH	4,604,391	08/05/86	Pfirmann	514	222	
	AI	4,626,536	12/02/86	Pfirmann	514	222	
	AJ	4,772,468	09/20/88	Pfirmann	424	128	
	AK	5,210,083	05/11/93	Pfirmann	514	222.5	
	AL	5,573,771	11/12/96	Geistlich et al.	424	422	
	AM	5,593,665	01/14/97	Pfirmann et al.	424	85.1	
	AN	5,819,748	10/13/98	Pfirmann	128	898	
	AO	5,972,933	10/26/99	Pfirmann	514	222.5	
	AP	5,954,687	09/21/99	Baudino	604	48	
	AQ	5,976,822	11/2/99	Landrum et al.	435	23	
	AR	6,011,030	01/04/00	Pfirmann	514	222.2	
	AS	6,080,397	06/27/00	Pfirmann et al.	424	78.08	
	AT	6,117,868	09/12/00	Pfirmann	514	222.5	

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	CD	Geistlich Catalog, "Taurolin, Triad antimicrobial chemotherapy" pp. 1-95.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/730,923
	Filing Date	December 6, 2000
	First Named Inventor	Paul Calabresi
	Group Art Unit	1619
	Examiner Name	Unknown
	Attorney Docket Number	21486-031

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	CE	Gormans et al. (1987) "Reduced Adherence of Micro-Organisms to Human Mucosal Epithelial Cells Following Treatment with Taurolin, a Novel Antimicrobial Agent," J. App. Bacteriol., 62:315-320
	CF	Hamik, A. et al. (1997) "Taurolidine Inhibits Tissue Factor Expression in Monocytes," <i>Abstract from the XVth Congress of the International Society on Thrombosis and Haemostasis</i> , Florence, June 6-12.
	CG	Jacobi, C. et al. (1999) "New Therapeutic Strategies to Avoid Intra- and Extraperitoneal Metastases during Laparoscopy: Results of a Tumor Model in the Rat," <i>Digestive Surgery</i> , Vol. 16 (5), pp. 393-399.
	CH	Jacobi, C. et al. (1997) "Inhibition of Peritoneal Tumor Cell Growth and Implantation in Laparoscopic Surgery in a Rat Model," <i>The American Journal of Surgery</i> , Vol. 174 (3), pp. 359-363.
	CI	Jacobi, C. et al. (1997) "Inhibition of Peritoneal Tumor Cell Growth and Implantation in Laparoscopic Surgery in a Rat Model," <i>The American Journal of Surgery</i> , Vol. 174 (3), pp. 359-363.
	CJ	Knight et al., (1983) "NMR Studies and GC Analysis of the Antibacterial Agent Taurolidine," J. Pharm. Sci. 72:705-707
	CK	Leaper et al. (1985) "Prevention of peritoneal adhesions after thermal injury using noxythidin and Taurolin" in a NEW CONCEPT IN ANTIMICROBIAL CHEMOTHERAPY FOR SURGICAL INFECTION, eds., WI Bruckner and RW Pfirman (Urban & Schwarzb: Munich, Vienna, Balt.), pages 115-119.
	CL	McCourt, M. et al. (2000) "Taurolidine Inhibits Tumor Cell Growth In Vitro and In Vivo," <i>Annals of Surgical Oncology</i> , Vol. 7(9), pp. :685-691.
	CM	Monson, J.R.T. et al. (1990) "Preliminary evidence that taurolidine is anti-neoplastic as well as anti-endotoxin and anti-microbial," <i>The British Journal of Surgery</i> , Vol. 77(6), pp. 711.
	CN	Monson, J.R.T. et al. (1990) "Taurolidine as an anti-neoplastic agent: a previously undiscovered role?" <i>The British Journal of Surgery</i> , Vol. 77(12).
	CO	Monson, J.R.T. et al., (1993) "Taurolidine inhibits tumor necrosis factor (TNF) toxicity new evidence of TNF and endotoxin synergy," <i>European Journal of Surgical Oncology</i> , 19:226-231.
	CP	Reymond, M.A. et al. (2000) "Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator," <i>Surgical Endoscopy</i> , Vol. 14(1), pp. 51-55.
	CQ	Umpleby, H. et al. (1984) "The efficacy of agents employed to prevent anastomotic recurrence in colorectal carcinoma," <i>Annals of the Royal College of Surgeons of England</i> , 66:192-194.
	CR	Volz J. et al. (2000) "Modulation of Tumor-Induced Lethality after Pneumoperitoneum in a Mouse Model," <i>Cancer</i> , Vol. 89(2), pp. 262-266.
	CS	Wicki, O. et al, (1983) "Solution for Surgical Lavage," <i>Langenbecks Archiv für Chirurgie</i> , p. 778, Abstract 276.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Calabresi *et al.*
ASSIGNEE: Rhode Island Hospital, A LifeSpan Partner
SERIAL NUMBER: 09/730,923 EXAMINER: Not Yet Assigned
FILING DATE: December 6, 2000 ART UNIT: 1619
FOR: USE OF TAUROLIDINE TO TREAT TUMORS

January 25, 2002
Boston, Massachusetts

Box IDS

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Supplemental Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of the International Search Report for the above-identified case. Accordingly, no fee or certification is believed required.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached modified Supplemental Form PTO-1449. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed Supplemental Form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

APPLICANTS: Calabresi *et al.*
U.S.S.N.: 09/730,923

Please charge any additional fees that may be due, or credit any overpayment of same, to
Deposit Account No. 50-0311 (Reference No. 23913-031).

Respectfully submitted,



Ingrid A. Beattie, Reg. No. 42,306
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: January 25, 2002

TRA 1622160v1

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/730,923
	Filing Date	December 6, 2000
	First Named Inventor	Paul Calabresi
	Group Art Unit	1619
	Examiner Name	M. Haghighatian
	Attorney Docket Number	23913-031 (formerly 21486-031)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	BH	WO	9403174	Pfirtmann	2/17/94	X	
	BI	WO	9006138	Pfirtmann	6/14/90	X	

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	CP	International Search Report.

* a copy of this reference is not provided as it was previously cited by or submitted to the office with the Information Disclosure Statement filed on August 22, 2001.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.